Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | HTR1B | P28222 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933202 | 0.96 | CA1 (0.49) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL4056753 | 0.96 | CA1 (0.51) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL1713420 | 0.92 | CA1 (0.61) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL29839512 | 0.92 | CA1 (0.61) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL30036529 | 0.91 | CYP1A2 (0.44) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL1179389 | 0.91 | L3MBTL1 (0.51) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL18159331 | 0.91 | HSD11B1 (0.47) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL4557839 | 0.90 | CA1 (0.55) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL15370576 | 0.89 | MEN1 (0.49) | CA1CA2CA9HSD11B1PPARG | |
| SCHEMBL1897441 | 0.89 | KMT2A (0.56) | CA1CA2CA9HSD11B1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10103401-B2 | Polymer electrolyte composition and polymer electrolyte membrane, polymer electrolyte membrane with catalyst layer, membrane electrode assembly, and polymer electrolyte fuel cell each using the same | TORAY INDUSTRIES, INC. (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-3131145-B1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | TORAY INDUSTRIES (JP) | 2018-09-05 | — | — | EP | disclosed |
| EP-2927283-B1 | POLYMER ELECTROLYTE COMPOSITION, AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE ELECTRODE COMPLEX AND SOLID POLYMER-TYPE FUEL CELL EACH PRODUCED USING SAME | TORAY INDUSTRIES (JP) | 2018-07-18 | — | — | EP | disclosed |
| EP-2669262-B1 | NOVEL ANTHRACENE COMPOUND AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME | JNC CORP (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2669262-B1 | NOVEL ANTHRACENE COMPOUND AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME | JNC CORP (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9748593-B2 | Polymer electrolyte composition, and polymer electrolyte membrane, membrane electrode complex and solid polymer-type fuel cell each produced using same | TORAY INDUSTRIES, INC. (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20170125832-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-3131145-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | Toray Industries, Inc. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-7981525-B2 | Naphthalene compound and organic light-emitting device using the compound | CANON KABUSHIKI KAISHA (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7452862-B2 | Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists | TRANZYME PHARMA, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-20080224603-A1 | NAPHTHALENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080224603-A1 | NAPHTHALENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20070267958-A1 | Material for Light Emitting Device and Light Emitting Device | TORAY INDUSTRIES, INC. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1783189-A1 | MATERIAL FOR LUMINESCENT ELEMENT AND LUMINESCENT ELEMENT | TORAY INDUSTRIES, INC. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1268495-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-02 | — | — | EP | disclosed |
| US-6465444-B2 | PROTEIN TYROSINE PHOSPHATASES(PTP-1B); ANTIDIABETIC, ANTITUMOR AND ANOREXIGENIC AGENTS; COMBINATION THERAPY | MERCK FROSST CANADA & CO. | 2002-10-15 | — | — | US | disclosed |
| US-20020002149-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-01-03 | — | — | US | disclosed |
| WO-2001070754-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080224603-A1 | NAPHTHALENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND | AHR, CRY1, NR2E3 | CA1 3542/4885CA2 3441/4885CA9 1915/4885 |
| US-20020002149-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | CA1 4360/4885CA2 2577/4885CA9 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.